Unlocking the potential of circulating miRNAs in the breast cancer neoadjuvant setting: a systematic review and meta-analysis
P Tiberio, M Gaudio, S Belloni, S Pindilli, C Benvenuti… - Cancers, 2023 - mdpi.com
Simple Summary In recent decades, neoadjuvant chemotherapy has proven to be a viable
therapeutic option, particularly in cases of high-risk early or locally advanced breast cancer …
therapeutic option, particularly in cases of high-risk early or locally advanced breast cancer …
The role of miRNAs as biomarkers in breast cancer
Breast cancer (BC) is the second most common cause of deaths reported in women
worldwide, and therefore there is a need to identify BC patients at an early stage as timely …
worldwide, and therefore there is a need to identify BC patients at an early stage as timely …
Potential role of genetic polymorphisms in neoadjuvant chemotherapy response in breast cancer
OE Bouhniz, A Kenani - Journal of Chemotherapy, 2024 - Taylor & Francis
Chemoresistance leads to treatment failure, which can arise through different mechanisms
including patients' characteristics. Searching for genetic profiles as a predictor for drug …
including patients' characteristics. Searching for genetic profiles as a predictor for drug …
Long-Term Outcomes of S-1 Combined With Low-Dose Docetaxel as Neoadjuvant Chemotherapy (N-1 Study, Phase II Trial) in Patients With Operable Breast Cancer
S Sasa, H Inoue, M Nakagawa, H Toba, M Goto… - Clinical Breast …, 2024 - Elsevier
Background We previously reported that S-1 and low-dose docetaxel (DOC)(N-1 study,
phase II trial) could be a well-tolerated and effective neoadjuvant chemotherapies (NACs) …
phase II trial) could be a well-tolerated and effective neoadjuvant chemotherapies (NACs) …